Yep. Unfortunately they now be at the point where they will need to dilute the hell out of the shares unless they do something radical and fast. Move out of Israel, get a new CEO. There is serious danger now of delisting. The &^& CEO may have permanently destroyed the stock. Biggest mistake was diluting into the rally last year for a signifiant discount. HUGE mistake. I am afraid a 1 to 10 reverse along with new headquarters is the only option.
They only registered because they know huge news is coming this year, sending the stock to 60 plus. That is a good time to sell shares to the public. Not now and they have absolutely no reason with 430 million in cash. And for earnings, ADRO has no revenues and in development! come on! Plus only missed estimates because milestone payment of 22 million is deferred. Otherwise they would have smoked estimates
This is great news! With the 8040 data, should have been up 400%. Instead down 15%. Need to get out of Israel. But that is another topic.
How much expected rev per year?? What are the royalty rates?? This is no-cost revenue too!! I wonder if it is enough to cover costs of 8040 development before a partner comes in. May also be enough so that an 8040 partner deal is more attractive (i.e. they dont need the cash as desperately now with 5010 rev)
I think we are right at the time frame for determining whether the drug is significant over chemo. I wonder if they are obliged to tell the public if they cut the study short for humanitarian reasons??
No change in data, so how did they get 16% chance of success from 35%?
Is there a proprietary algorithm that changed its calculation? If so, then they dont need an analyst, just give credit to the algorithm writers and keep it 100% objective and constantly changing.
If it is not an algorithm, how did they calculate and why did it change so much with no data?. Sounds like a "pull out of the hat" number and, therefore, totally subjective to the whims and moods of the analyst and, thus, WORTHLESS
Yes, given no new data, to "change your mind" is a poor analyst strategy whether they are right or wrong. It is amateur and unprofessional. Expect more from BofA.
Crooked analyst had a 40 price target on ADRO and loved the drug prospects. Now 14. What happened?? Suddenly hates the prospects? insider info on the trial?
compared to estimate of 14 cent loss. 431 million in cash. Novartis deal and others. Both ADRO and ADXS are in my portfolio. how about you?
Lowest level since Sept. smart shorts getting out with the carnage. They certainly were lucky the market cooperated with them. Lets see how many dumb shorts are left in 3 months with a rebound to 20??
Should be close to 475 million in cash i believe. So we are trading at 800 million market cap, so the market prices the technology at 325 million. That is crazy. ADXS technology priced at 90 million.
If I were Novartis, I would buy both now. ADXS for 18 a share and ADRO for 30. Screaming deal for everyone now except those who bought at the peak. For under 1.5 billion (subtracting cash) Novartis could totally own this technology